Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
No Thumbnail Available
Authors
Randall, Leslie M.
Sill, Michael W.
Burger, Robert A.
Monk, Bradley J.
Buening, Barbara
Sorosky, Joel I.
Issue Date
2012
Type
Journal Article
Language
Keywords
Alternative Title
Abstract
Description
Citation
Randall, Leslie M.; Sill, Michael W.; Burger, Robert A.; Monk, Bradley J.; Buening, Barbara; Sorosky, Joel I. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic oncology. 2012, 124(3):563-568.
Publisher
License
Journal
Volume
Issue
PubMed ID
DOI
ISSN
0090-8258
1095-6859
1095-6859